Purin-Ago: Non-nucleotide agonists of the P2Y11-receptor with immunosuppressant effect
Purinergic receptors have been in the focus of drug discovery for many years. This invention provides nonnucleotide
agonists of the P2Y11-receptor. The agonists ensure high specificity among P2-receptors which is a key to tolerability of compounds meant for applications in longterm treatment settings. Activation of the P2Y11-receptor leads to a variety of effects in the modulation of immune system activity. For example release of immune modulatory thrombospondin-1 is induced, while lipopolysaccharide (LPS)-stimulated release of the pro-inflammatory cytokine interleukin-12 (IL- 12) is inhibited by activation of the P2Y11-receptor.
Further Information: PDF
PROvendis GmbH
Phone: +49 (0)208/94105 0
Contact
Dipl.-Ing. Alfred Schillert
Media Contact
All latest news from the category: Technology Offerings
Newest articles
High-energy-density aqueous battery based on halogen multi-electron transfer
Traditional non-aqueous lithium-ion batteries have a high energy density, but their safety is compromised due to the flammable organic electrolytes they utilize. Aqueous batteries use water as the solvent for…
First-ever combined heart pump and pig kidney transplant
…gives new hope to patient with terminal illness. Surgeons at NYU Langone Health performed the first-ever combined mechanical heart pump and gene-edited pig kidney transplant surgery in a 54-year-old woman…
Biophysics: Testing how well biomarkers work
LMU researchers have developed a method to determine how reliably target proteins can be labeled using super-resolution fluorescence microscopy. Modern microscopy techniques make it possible to examine the inner workings…